OPEN END TURBO SHORT - NOVO-NORDISK B | Market Closed - Börse Stuttgart 12:57:06 29/05/2024 am IST | ||
| 2.63 EUR | +3.14% |
|
| Current month | -12.33% | ||
| 1 month | -14.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.63 | +3.14% |
| 27/24/27 | 2.55 | +3.24% |
| 24/24/24 | 2.47 | +6.93% |
| 23/24/23 | 2.31 | -12.17% |
| 22/24/22 | 2.63 | +2.73% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 12:57 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG01ZY |
| ISIN | DE000MG01ZY2 |
| Date issued | 11/03/2024 |
| Strike | 1,116 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.85 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.72 € |
|---|---|
| Lowest since issue | 2.31 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
